Key Takeaways
- A 42.6 percent nonresponse rate raises questions about sweeping claims of minimal regret after adolescent hormone treatment.
- The article confuses average follow-up time with minimum follow-up time, overstating what researchers established about long-term outcomes.
- Minors’ reports of inadequate preparation underscore the stakes of informed consent and rigorous scrutiny of treatment guidelines.






Comments